Journal article

LGG-59. REMARKABLE OBJECTIVE RESPONSE AND FAVORABLE SURVIVAL FOR BRAF-V600E CHILDHOOD LOW-GRADE GLIOMAS TO BRAF INHIBITORS COMPARED CONVENTIONAL CHEMOTHERAPY

Michal Zapotocky, Scott Ryall, Kohei Fukuoka, Ana Guerreiro Stucklin, Julie Bennett, David Sumerauer, Zdenek Pavelka, Ofelia Cruz, Palma Solano, Maria Luisa Garre, Peter Hauser, Didier Frappaz, Jordan Hansford, Nisreen Amayiri, Helena Morse, Magnus Sabel, Anne Grete Bechensteen, Jack Su, Matthias Karajannis, Jonathan Finlay Show all

Neuro-oncology | Oxford University Press (OUP) | Published : 2018

Abstract

Abstract Activation of the MAPK pathway represents a hallmark of pediatric low-grade glioma (pLGG) and is frequently caused by BRAF alterations. BRAF-V600E represent an aggressive type of pLGG with less than optimal response to conventional chemo-radiation approaches. While clinical trials using BRAF-V600E inhibitors are ongoing, these data are not yet available. We have assembled an international cohort of BRAF-V600E glioma patients treated off-label with BRAF inhibitors as a monotherapy. Complete molecular, clinical and imaging data is being collected and compared to previous chemo-radiation therapies. Ongoing data form the taskforce on 40 BRAF-V600E gliomas from 25 international instituti..

View full abstract